Ketamine and Depression: What the Research Shows

Ketamine has become an important area of depression research because some people experience improvement more quickly than with many conventional antidepressants.

At the same time, public conversations about ketamine can be confusing. Ketamine, esketamine, and arketamine are related but different. Their FDA status is not the same, and the amount of research supporting each one varies.

Understanding these differences can make it easier to interpret new studies, headlines, and treatment discussions.

Ketamine has been used in medicine as an anesthetic since the 1970s.

Standard ketamine, sometimes called racemic ketamine, contains two mirror-image forms of the same molecule: R-ketamine and S-ketamine.

Researchers later discovered that ketamine appeared to reduce depressive symptoms rapidly in some people, particularly those with treatment-resistant depression. This finding led to decades of research into its possible psychiatric uses.

Racemic ketamine is FDA approved as an anesthetic. When healthcare professionals prescribe it for depression, they are using it off-label.

Esketamine contains only the S-ketamine portion of the ketamine molecule.

It is available as the prescription nasal spray Spravato and has received FDA approval for certain depressive conditions.

Esketamine is administered in certified healthcare settings because it can temporarily cause effects such as sedation, dissociation, changes in blood pressure, and impaired coordination.

Although ketamine and esketamine are closely related, research findings about one should not automatically be applied to the other. They may be administered differently and studied using different doses, treatment schedules, and patient populations.

Much of the research has focused on treatment-resistant depression, or TRD.

Treatment-resistant depression generally describes major depressive disorder that has not adequately improved after multiple appropriate treatment attempts.

Ketamine attracted attention because some studies found improvements in depressive symptoms within hours or days for some participants.

Researchers believe this may be related to ketamine’s effects on the brain’s glutamate system.

Ketamine interacts with NMDA receptors and appears to influence other processes involved in brain communication and synaptic plasticity. Scientists are also studying pathways involving AMPA receptors, BDNF, and mTOR.

The exact mechanism responsible for ketamine’s antidepressant effects is still being investigated.

Clinical trials and systematic reviews have found that ketamine and esketamine can reduce depressive symptoms in some people, including people with treatment-resistant depression.

Research also suggests that improvement does not always happen at the same pace.

For example, a 2026 analysis of the ESCAPE-TRD study found that some people receiving esketamine continued improving after the first several weeks of treatment. Some participants who had not reached remission early in treatment later did so.

These findings are useful, but they do not mean everyone will respond or that treatment should automatically continue when someone is not improving.

Researchers still need to understand why some people respond quickly, why others respond more gradually, and why some do not respond.

Ketamine and esketamine can cause short-term side effects including dizziness, nausea, sedation, dissociation, headache, changes in perception, and temporary increases in blood pressure.

Most treatment-day effects resolve as the medication wears off.

Researchers now have more information about repeated ketamine and esketamine treatment than they did during the early years of psychiatric research. Long-term studies of medically monitored treatment have generally been reassuring, but important questions remain about treatment lasting many years and about differences between dosing schedules and routes of administration.

Frequent, high-dose recreational ketamine use has been associated with more serious problems, including bladder injury, tolerance, and dependence. These risks should not automatically be applied to medically supervised treatment, but they show why dose, frequency, medical history, and monitoring matter.

Arketamine, also called R-ketamine, is the other mirror-image form of ketamine.

Researchers became interested in arketamine after laboratory and animal studies suggested it might have antidepressant properties that differ from esketamine.

Human research is still limited, and findings have been mixed.

Arketamine is not FDA approved for depression or any other psychiatric condition. It remains an investigational treatment.

This is an important example of why promising early research should be separated from established clinical evidence.

Ketamine research has changed how scientists think about depression.

It demonstrated that antidepressant effects may occur through biological pathways beyond those targeted by many traditional antidepressants, and that improvement can sometimes occur much more rapidly.

But “ketamine treatment” is a broad term.

Racemic ketamine, esketamine, and arketamine have different evidence bases and regulatory histories. How a medication is administered, how frequently it is used, and how closely someone is monitored can also affect both potential benefits and risks.

Understanding these differences helps people evaluate new research without assuming that every finding about one type of ketamine applies to all of them.

Ketamine has been studied extensively for depression, particularly treatment-resistant depression, and research suggests that some people may experience rapid reductions in depressive symptoms.

Racemic ketamine is FDA approved as an anesthetic and may be prescribed off-label for depression. Esketamine is FDA approved for certain depressive conditions and is administered under medical supervision. Arketamine remains investigational.

Researchers are continuing to study long-term safety, maintenance treatment, differences between ketamine formulations, and why treatment responses vary so much between individuals.

Ketamine research covers a wide range of questions, from how these medications affect the brain to differences between ketamine, esketamine, and emerging compounds such as arketamine.

Unlimited Sciences is continuing to explore these topics through our Ultimate Guide to Ketamine series. As new articles are published, additional resources will be added here for readers who want to explore specific areas of the research in greater depth.